Sunday, November 3, 2024
HomeTagsNYHA

NYHA

U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS (mavacamten) Label

Bristol Myers Squibb, announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics